Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys combination therapy versus untreated control in children with immune-tolerant HBeAg-positive chronic hepatitis B
2006-000977-31Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa, lamivudine and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoint: Loss of HBsAg at 24 weeks post-end of treatment/end of untreated observation. Started Mar 2006; status: completed.
02
Drugs
interferon alfalamivudineentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2006-000977-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000977-31.